{"id":34882,"date":"2015-04-21T12:02:13","date_gmt":"2015-04-21T16:02:13","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=34882"},"modified":"2015-04-21T12:02:13","modified_gmt":"2015-04-21T16:02:13","slug":"nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882","title":{"rendered":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Nymox Pharmaceutical Corporation (NASDAQ:NYMX)<\/strong> <a href=\"http:\/\/finance.yahoo.com\/news\/nymox-announces-prostate-cancer-clinical-140000472.html\">reported<\/a> long-term clinical study results from its NX-1207 Phase II prostate cancer trial NX03-0040. The new findings reflect statistically significant better results at up to 2.8 years for \u201cNX-1207\u201d treated patients as compared to controls. The study included 146 enrollments suffering with low-grade localized prostate cancer. The study was carried out at 44 U.S. investigational locations.<\/p>\n<p style=\"text-align: justify;\"><strong>The study<\/strong><\/p>\n<p style=\"text-align: justify;\">In the trial, Nymox conducted a controlled comparison of patients who needed and received radiation and surgery cure for their cancer. They were based on blinded after treatment upgraded assessments of their pre-treatment. The trial concluded that after up to 2.8 years for single-injection of NX-1207 treated enrollments, there was a 68.2% reduction. The new trial also concluded that all instances of radiation or surgery, including elective cases dropped by 62.7% in NX-1207 enrollments against the randomized control group. The long-term result is a vital measure of drug treatment efficacy.<\/p>\n<p style=\"text-align: justify;\"><strong>The management speaks<\/strong><\/p>\n<p style=\"text-align: justify;\">Paul Averback MD, the CEO of Nymox Pharmaceutical Corporation (NASDAQ:NYMX)\u00a0stated that these new results reflect the potential of NX-1207 to treat people with low-grade prostate cancer. It provides a tangible advantage in terms of avoidance of surgery and\/or radiation and the associated side effects, risks and discomforts. The results indicate a considerable positive impact from a single painless injection.<\/p>\n<p style=\"text-align: justify;\"><strong>\u00a0The profile<\/strong><\/p>\n<p style=\"text-align: justify;\">To date, Nymox\u2019s NX-1207 reflected an excellent safety profile. It showed safety in nine clinical studies of prostate and BPH cancer including repeat injection trials. The drug candidate does not result in immune responses like antibody formation. All these can cause drastic drug toxicity and limited usage to single treatments. NX-1207 treatment has shown to have no major adverse effect after treatment on testosterone levels or sexual function. Prostate cancer is one of the most commonly seen cancers in men, and is second major factor of cancer death in men.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported long-term clinical study results from its NX-1207 Phase II prostate cancer trial NX03-0040. The new findings reflect statistically significant better [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":33033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2905,11227,11228],"stock_ticker":[],"class_list":["post-34882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqnymx","tag-nymox-pharmaceutical-corporation-nasdaqnymx","tag-paul-averback","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported long-term clinical study results from its NX-1207 Phase II prostate cancer trial NX03-0040. The new findings reflect statistically significant better [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-21T16:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results\",\"datePublished\":\"2015-04-21T16:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882\"},\"wordCount\":319,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"keywords\":[\"NASDAQ:NYMX\",\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX)\",\"Paul Averback\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882\",\"name\":\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"datePublished\":\"2015-04-21T16:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882","og_locale":"en_US","og_type":"article","og_title":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results - Wall Street PR","og_description":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported long-term clinical study results from its NX-1207 Phase II prostate cancer trial NX03-0040. The new findings reflect statistically significant better [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-04-21T16:02:13+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results","datePublished":"2015-04-21T16:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882"},"wordCount":319,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","keywords":["NASDAQ:NYMX","Nymox Pharmaceutical Corporation (NASDAQ:NYMX)","Paul Averback"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882","url":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882","name":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","datePublished":"2015-04-21T16:02:13+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-reports-new-prostate-cancer-clinical-trial-results-34882#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/34882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=34882"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/34882\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/33033"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=34882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=34882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=34882"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=34882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}